Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy

ToplineDanish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy.Wegovy is an injectable weight loss medicine that has helped Novo Nordisk profits soar. UCG/Universal Images Group via Getty Images Key FactsNovo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first t ...